BioAtla to Present Innovative Cancer Treatment Data Soon
BioAtla Announces Key Presentation at Notable Cancer Meeting
BioAtla, Inc. (NASDAQ: BCAB), a pioneering player in clinical-stage biotechnology, is set to showcase its advancements in the field of cancer therapeutics at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. This significant event, which runs from November 8 to November 10, 2024, will take place at the George R. Brown Convention Center.
Presentation Overview
The poster presentation will feature updated findings from a pivotal phase 1 study investigating evalstotug (BA3071), a cutting-edge anti-CTLA-4 conditionally active biologic. This promising therapy has been evaluated both independently and in conjunction with nivolumab, targeting advanced solid tumors.
Details of the Presentation
The presentation will delve into the following key details:
- Title: Updated results from a phase 1 study of evalstotug (BA3071)
- Authors: Jacob Thomas, Eva Selfridge, Costantine Albany among others
- Abstract Number: 497
- Date & Time: November 8, 2024, at 9:00 AM CDT
- Location: Exhibit Halls AB
About BioAtla and Its Innovations
BioAtla stands out as a global leader in biotechnology, focusing intently on the innovative development of Conditionally Active Biologics (CAB). This groundbreaking approach allows the formulation of highly selective and efficient biopharmaceutical products designed to treat solid tumors while minimizing systemic toxicity.
Technological Advancements
By employing proprietary technology, BioAtla creates biologics that are not only effective but also more cost-efficient than traditional antibodies. The company's CAB candidates are continuously demonstrating improved safety profiles, making them suitable for combination therapies with other immune checkpoint inhibitors.
Regulatory and Clinical Progress
BioAtla has a robust pipeline, including two first-in-class CAB programs currently in Phase 2 clinical testing. These include:
- Mecbotamab vedotin: An AXL-targeted antibody-drug conjugate designed to directly combat tumor malignancies.
- Ozuriftamab vedotin: A unique ROR2-targeted antibody-drug conjugate aimed at enhancing treatment responses in difficult-to-treat cancer types.
Furthermore, their dual CAB bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 development, showcasing BioAtla's commitment to advancing cancer treatments.
Patent Coverage and Future Directions
With over 765 active patent matters, including 500 issued patents, BioAtla enjoys comprehensive patent protection across major global markets. This protection encompasses various methods of manufacturing and screening CAB therapies, ensuring a competitive edge in the biopharmaceutical landscape.
Connect with BioAtla
For further information about BioAtla and its pioneering research, interested parties can explore the company's official website. Engage with BioAtla's scientific developments and stay updated on innovative therapies shaping the future of cancer treatment.
Company Contacts
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
Email: rwaldron@bioatla.com
Phone: 858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
Email: bmackle@lifesciadvisors.com
Frequently Asked Questions
What is BioAtla's main focus?
BioAtla focuses on developing advanced biologic therapies for cancer treatment through its unique CAB technology.
What significant event is BioAtla participating in?
BioAtla is presenting at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
What is evalstotug?
Evalstotug is an anti-CTLA-4 conditionally active biologic being studied for its effects on advanced solid tumors.
What clinical stages are BioAtla’s products currently in?
BioAtla has multiple products in various clinical stages, with significant ones in Phase 2 trials.
Where can I find more information about BioAtla?
You can find more information by visiting the official BioAtla website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Brady Board Member's Strategic Stock Purchase Signals Growth
- Brady Director's $135K Stock Purchase Sparks Investor Interest
- Evaluating AMD and Rival Firms in Semiconductor Landscape
- Joanne Smee Collins Investor Confidence Fuels Brady Stock Purchase
- Elizabeth Michelle Williams Makes Strategic $135K Brady Stock Acquisition
- Naples Soap Company's Strategic Move with Reverse Stock Split
- Broadcom CEO Hock E Tan Sells Shares: What Investors Should Know
- Avalanche's Price Surge: What You Need to Know Today
- Investors Should Act Now in Lululemon Class Action Lawsuit
- Bone Health Foundation Receives CDC Grant to Boost Awareness
Recent Articles
- Kineta's KVA12123 to Be Showcased at Major Cancer Conference
- Interface, Inc. Plans Q3 2024 Earnings Call and Insights
- NextCure to Present Innovative Cancer Research at SITC Meeting
- SkyWest Schedules Q3 2024 Earnings Call: What to Expect
- Elis Reassesses Strategic Opportunities Following Discussions
- Popular, Inc. Announces Preferred Stock Dividend Updates
- TScan Therapeutics Reveals Key Presentations for SITC Annual Meeting
- California Resources Corporation Empowers Rams' Carbon Journey
- Cloud Theory Reports Record New Vehicle Inventory Growth
- Exploring Middlefield Canadian Income's Latest Asset Value Insights
- Medicenna Unveils Innovative Data at Leading Cancer Meeting
- ODDSworks Enters Mexican iGaming Market with Novibet
- Exploring SP Group A/S Share Buy-Back Program Details
- Exciting New Development: Hard Rock Hotel Malta Underway
- Tellurian's Stockholders Approve Significant Merger Agreement
- Insights from MiNK Therapeutics' iNKT Cell Programs Presentations
- Grammarly Recognized as Leader in Generative AI Solutions
- FDA Takes Bold Action: 16 New Cancer Therapies Approved Recently
- Investigation of CrowdStrike’s Leadership for Possible Failures
- Discover Secret Strategies for Affordable Holiday Travel
- Celebrating Excellence: 2024 ISG Paragon Awards Winners Announced
- DuPont Enhances Photoresist Production Capacity in Japan Facility
- Janus Henderson's Q3 2024 Results and Investor Call Details
- Moleculin Biotech Announces Engaging Conferences for Investors
- SilverBox Corp IV Launches Trading of Class A Shares and Warrants
- Healthy.io Receives Digital Health Awards Finalist Recognition
- FBFK Law Facilitates Major Acquisition in Tech Sector
- Allergan Aesthetics Partners with Girls Inc. to Empower Future STEM Leaders
- Bitwise Asset Management Transitions ETFs With Innovative Strategies
- SS&C Technologies to Announce Q3 2024 Financial Results Soon
- Understanding Copart's P/E Ratio and Market Position
- Optomi Professional Services Welcomes New Chief Revenue Officer
- Apple Expands Retail Presence in India with New Stores
- Celebrating Excellence in Healthcare Marketing at the Gala
- Exploring Telegram's Privacy Changes: Impact on Social Media Landscape
- HotSpot Therapeutics Unveils Promising Data on HST-1011
- Newterra Enhances Water Treatment Capabilities in Southeast
- Phoenix Children's Enhances Leadership for Comprehensive Care
- Cullen/Frost Bankers, Inc. Announces Earnings Call for Q3 2024
- Russel Metals Announces Investor Conference Call Details
- New Members Appointed to Vitrolife AB's Election Committee
- Sugar Grove Ace Commemorates a Decade of Community Support
- Immuron Ltd's Promising Progress in Biopharmaceutical Research
- IREN Expands Bitcoin Mining and AI Services to New Heights
- Wells Fargo Highlights Earnings Guidance Concerns for J&J
- Nvidia Insights: Selling Spree, Predictions, and Innovations
- First Western Financial to Share Q3 2024 Results and Insights
- US Labor Market Surprises with Strong Job Growth Data
- Verizon's Upcoming Earnings Report: What Investors Should Know
- Resignation at Trump Media Signals Changes Ahead for TMTG